Genzyme Corporation (GENZ) and Isis Pharmaceuticals, Inc. (ISIS) Announce Submission of European Marketing Authorization Application for Mipomersen (Kynamro(R))  
7/28/2011 8:22:25 AM

CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that Genzyme has submitted a marketing authorization application (MAA) to the European Medicines Agency seeking approval for the 200 mg weekly dose of mipomersen for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.